射血分数保留的心力衰竭患者心肌基因表达特征
该研究对41例HFpEF患者、30例HFrEF患者和24例供体对照的右心室间隔心内膜心肌活检组织进行RNA测序,发现HFpEF具有独特的广泛转录组特征和分子亚组,与HFrEF及对照明显分离,且这些差异不能完全由合并症解释。HFpEF中独特上调的基因富集于线粒体ATP合成/电子传递通路,而HFrEF中该通路下调。非负矩阵分解识别出3个HFpEF转录组亚组,具有不同通路和临床相关性。
要点
- HFpEF心肌转录组与HFrEF及供体对照明显不同,校正主要合并症后仍持续存在。
- HFpEF独特上调基因富集于线粒体ATP合成/电子传递,而HFrEF中该通路下调。
- HFpEF存在3个转录组亚组,其中一组接近HFrEF且死亡率更高,另一组多为女性、心脏较小伴促炎信号。
核心结论
- HFpEF表现出独特的广泛转录组特征和分子亚组,具有特定临床特征和结局,揭示了精准治疗的新信号靶点。
研究设计与样本
- 前瞻性获取符合HFpEF共识标准的患者右心室间隔心内膜心肌活检组织(n=41),与HFrEF患者(n=30)和供体对照(n=24)的右心室间隔组织进行RNA测序对比。
主要发现
- 主成分分析显示HFpEF与HFrEF及供体对照分离,重叠极少,校正BMI、性别、年龄、糖尿病和肾功能后仍持续。
- HFpEF与对照相比有1882个基因上调、2593个基因下调;其中近一半改变方向与HFrEF相同,但HF两组间有5745个基因改变独特。
- HFpEF独特上调基因富集于线粒体ATP合成/电子传递通路,而HFrEF中该通路下调;HFpEF特异性下调基因涉及内质网应激、自噬和血管生成。
- BMI差异 largely 解释HFpEF上调基因,但下调基因富集的通路不受此或更广泛合并症校正影响。
- 非负矩阵分解识别3个HFpEF转录组亚组,包括一个最接近HFrEF且死亡率更高的组和一个多为女性、心脏较小伴促炎信号的组;加权基因共表达分析得到类似基因簇和临床分组。
临床怎么用
- HFpEF患者心肌存在可区分的转录组特征,提示应考虑针对特定分子亚组的精准治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure (HF) with preserved ejection fraction (HFpEF) constitutes half of all HF but lacks effective therapy. Understanding of its myocardial biology remains limited because of a paucity of heart tissue molecular analysis. METHODS: We performed RNA sequencing on right ventricular septal endomyocardial biopsies prospectively obtained from patients meeting consensus criteria for HFpEF (n=41) contrasted with right ventricular septal tissue from patients with HF with reduced ejection fraction (HFrEF, n=30) and donor controls (n=24). Principal component analysis and hierarchical clustering tested for transcriptomic distinctiveness between groups, effect of comorbidities, and differential gene expression with pathway enrichment contrasted HF groups and donor controls. Within HFpEF, non-negative matrix factorization and weighted gene coexpression analysis identified molecular subgroups, and the resulting clusters were correlated with hemodynamic and clinical data. RESULTS: Patients with HFpEF were more often women (59%), African American (68%), obese (median body mass index 41), and hypertensive (98%), with clinical HF characterized by 65% New York Heart Association Class III or IV, nearly all on a loop diuretic, and 70% with a HF hospitalization in the previous year. Principal component analysis separated HFpEF from HFrEF and donor controls with minimal overlap, and this persisted after adjusting for primary comorbidities: body mass index, sex, age, diabetes, and renal function. Hierarchical clustering confirmed group separation. Nearly half the significantly altered genes in HFpEF versus donor controls (1882 up, 2593 down) changed in the same direction in HFrEF; however, 5745 genes were uniquely altered between HF groups. Compared with controls, uniquely upregulated genes in HFpEF were enriched in mitochondrial adenosine triphosphate synthesis/electron transport, pathways downregulated in HFrEF. HFpEF-specific downregulated genes engaged endoplasmic reticulum stress, autophagy, and angiogenesis. Body mass index differences largely accounted for HFpEF upregulated genes, whereas neither this nor broader comorbidity adjustment altered pathways enriched in downregulated genes. Non-negative matrix factorization identified 3 HFpEF transcriptomic subgroups with distinctive pathways and clinical correlates, including a group closest to HFrEF with higher mortality, and a mostly female group with smaller hearts and proinflammatory signaling. These groupings remained after sex adjustment. Weighted gene coexpression analysis yielded analogous gene clusters and clinical groupings. CONCLUSIONS: HFpEF exhibits distinctive broad transcriptomic signatures and molecular subgroupings with particular clinical features and outcomes. The data reveal new signaling targets to consider for precision therapeutics.
引用
- Hahn VS, Knutsdottir H, Luo X, et al. Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction. Circulation. 2020. PMID: 33118835. doi:10.1161/CIRCULATIONAHA.120.050498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。